Our top pick for
Building a portfolio
Bicycle Therapeutics plc is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Bicycle Therapeutics employs 87 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$12.31 - $33.00|
|50-day moving average||$26.58|
|200-day moving average||$21.84|
|Wall St. target price||$36.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-14.16|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Bicycle Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bicycle Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bicycle Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1839x. In other words, Bicycle Therapeutics shares trade at around 1839x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||$10.4 million|
|Gross profit TTM||$-22,759,000|
|Return on assets TTM||-23.94%|
|Return on equity TTM||-54.08%|
|Market capitalisation||$598.7 million|
TTM: trailing 12 months
There are currently 441,460 Bicycle Therapeutics shares held short by investors – that's known as Bicycle Therapeutics's "short interest". This figure is 10.3% up from 400,080 last month.
There are a few different ways that this level of interest in shorting Bicycle Therapeutics shares can be evaluated.
Bicycle Therapeutics's "short interest ratio" (SIR) is the quantity of Bicycle Therapeutics shares currently shorted divided by the average quantity of Bicycle Therapeutics shares traded daily (recently around 159949.27536232). Bicycle Therapeutics's SIR currently stands at 2.76. In other words for every 100,000 Bicycle Therapeutics shares traded daily on the market, roughly 2760 shares are currently held short.
However Bicycle Therapeutics's short interest can also be evaluated against the total number of Bicycle Therapeutics shares, or, against the total number of tradable Bicycle Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bicycle Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Bicycle Therapeutics shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Bicycle Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bicycle Therapeutics.
Find out more about how you can short Bicycle Therapeutics stock.
We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.